Iovance Biotherapeutics Inc (NASDAQ:IOVA) – Equities researchers at Jefferies Group issued their Q3 2018 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a research report issued to clients and investors on Monday, March 12th, according to Zacks Investment Research. Jefferies Group analyst B. Amin forecasts that the biotechnology company will post earnings of ($0.31) per share for the quarter. Jefferies Group has a “Buy” rating and a $31.00 price objective on the stock. Jefferies Group also issued estimates for Iovance Biotherapeutics’ FY2018 earnings at ($1.22) EPS, FY2019 earnings at ($1.21) EPS, FY2020 earnings at ($1.29) EPS and FY2021 earnings at ($0.57) EPS.
A number of other equities research analysts have also recently issued reports on the company. BidaskClub cut Iovance Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. ValuEngine raised Iovance Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. HC Wainwright set a $22.00 target price on Iovance Biotherapeutics and gave the stock a “buy” rating in a research report on Tuesday, March 13th. B. Riley upped their price target on Iovance Biotherapeutics from $18.50 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, March 13th. Finally, Oppenheimer upped their price target on Iovance Biotherapeutics from $13.00 to $19.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $19.72.
Iovance Biotherapeutics stock traded down $0.55 during trading hours on Thursday, reaching $13.85. 902,894 shares of the company were exchanged, compared to its average volume of 979,769. The stock has a market capitalization of $1,288.02, a P/E ratio of -9.82 and a beta of 5.75. Iovance Biotherapeutics has a 12 month low of $4.45 and a 12 month high of $19.90.
Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Monday, March 12th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.04).
Several hedge funds have recently modified their holdings of IOVA. Orbimed Advisors LLC lifted its holdings in shares of Iovance Biotherapeutics by 89.9% during the third quarter. Orbimed Advisors LLC now owns 6,425,626 shares of the biotechnology company’s stock worth $49,799,000 after buying an additional 3,042,726 shares during the last quarter. Vanguard Group Inc. acquired a new position in shares of Iovance Biotherapeutics during the second quarter worth approximately $16,113,000. Farallon Capital Management LLC lifted its holdings in shares of Iovance Biotherapeutics by 119.6% during the fourth quarter. Farallon Capital Management LLC now owns 1,866,900 shares of the biotechnology company’s stock worth $14,935,000 after buying an additional 1,016,900 shares during the last quarter. State Street Corp acquired a new position in shares of Iovance Biotherapeutics during the second quarter worth approximately $7,286,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Iovance Biotherapeutics by 63.4% in the third quarter. JPMorgan Chase & Co. now owns 1,779,700 shares of the biotechnology company’s stock valued at $14,059,000 after purchasing an additional 690,527 shares in the last quarter. Institutional investors own 64.44% of the company’s stock.
WARNING: “Iovance Biotherapeutics Inc to Post Q3 2018 Earnings of ($0.31) Per Share, Jefferies Group Forecasts (NASDAQ:IOVA)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/04/07/analysts-offer-predictions-for-iovance-biotherapeutics-incs-q3-2018-earnings-iova.html.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.